<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04836494</url>
  </required_header>
  <id_info>
    <org_study_id>CoA-101</org_study_id>
    <nct_id>NCT04836494</nct_id>
  </id_info>
  <brief_title>A First in Human, Dose Escalation Study to Evaluate the Safety and Tolerability of BBP-671 in Healthy Volunteers and Patients With Propionic Acidemia or Methylmalonic Acidemia</brief_title>
  <official_title>A First-in-human, Randomized, Placebo-controlled, Single and Multiple Ascending Dose Escalation to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BBP-671 in Healthy Subjects and In Patients With Propionic Acidemia or Methylmalonic Acidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CoA Therapeutics, Inc., a BridgeBio company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CoA Therapeutics, Inc., a BridgeBio company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, PK and PD of BBP-671 in&#xD;
      healthy volunteers and patients with Propionic Acidemia or Methylmalonic Acidemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is the first-in-human study with BBP-671 and is designed to provide healthy sbujects&#xD;
      single- and multiple-dose and patient multidose safety, tolerability, PK, and PD data&#xD;
      regarding BBP-671 for future clinical studies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2021</start_date>
  <completion_date type="Anticipated">July 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 28, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events following administration of BBP-671</measure>
    <time_frame>43 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>BBP-671 concentration dependent change in change from baseline in QTcF</measure>
    <time_frame>43 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Assessments: Cmax</measure>
    <time_frame>43 days</time_frame>
    <description>Time to maximum concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Assessments: Tmax</measure>
    <time_frame>43 days</time_frame>
    <description>Time to reach maximum observed plasma concentration (Tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Assessments: t1/2</measure>
    <time_frame>43 days</time_frame>
    <description>Plasma decay half-life (t1/2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Assessments: AUC</measure>
    <time_frame>43 days</time_frame>
    <description>Area under the plasma concentration-time curve (AUC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Assessments: CL/F</measure>
    <time_frame>43 days</time_frame>
    <description>Apparent clearance (CL/F)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Assessments: Vz/F</measure>
    <time_frame>43 days</time_frame>
    <description>Apparent volume of distribution (Vz/F)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Assessments: CLr</measure>
    <time_frame>43 days</time_frame>
    <description>Renal clearance (CLr)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Food Effect: Cmax</measure>
    <time_frame>10 days</time_frame>
    <description>Time to maximum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food Effect: Tmax</measure>
    <time_frame>10 days</time_frame>
    <description>Time to reach maximum observed plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Food Effect: AUC</measure>
    <time_frame>10 days</time_frame>
    <description>Area under the plasma concentration-time curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic Assessment: Whole blood and plasma biomarker concentrations will be quantified and summarized using appropriate descriptive parameters</measure>
    <time_frame>43 days</time_frame>
    <description>Measurement will be done using liquid chromatography-tandem mass spectrometry</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">128</enrollment>
  <condition>Healthy Volunteers</condition>
  <condition>Propionic Acidemia</condition>
  <condition>Methylmalonic Acidemia</condition>
  <condition>Organic Acidemia</condition>
  <arm_group>
    <arm_group_label>BBP-671 for SAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The SAD portion of the study will consist of up to 8 cohorts. Six (6) healthy male or female adult subjects will be randomized to receive BBP-671 per cohort (6:2 ratio, BBP-671:placebo).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for SAD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The SAD portion of the study will consist of up to 8 cohorts. Two (2) healthy male or female adult subjects will be randomized to receive matching placebo per cohort (6:2 ratio, BBP-671:placebo).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BBP-671 for MAD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The MAD portion of the study will consist of up to 6 cohorts. Six (6) healthy male or female adult subjects will be randomized to receive BBP-671 per cohort (6:2 ratio, BBP-671:placebo).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo for MAD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The MAD portion of the study will consist of up to 6 cohorts. Two (2) healthy male or female adult subjects will be randomized to receive matching placebo per cohort (6:2 ratio, BBP-671:placebo).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BBP-671 for SAD Food Effect</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eight (8) healthy male or female adult subjects will be randomized to receive BBP-671.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BBP-671 for PA and MMA Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Up to eight (8) PA patients and eight (8) MMA patients will receive BBP-671.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BBP-671</intervention_name>
    <description>BBP-671, oral suspension</description>
    <arm_group_label>BBP-671 for MAD</arm_group_label>
    <arm_group_label>BBP-671 for PA and MMA Patients</arm_group_label>
    <arm_group_label>BBP-671 for SAD</arm_group_label>
    <arm_group_label>BBP-671 for SAD Food Effect</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo matching BBP-671</description>
    <arm_group_label>Placebo for MAD</arm_group_label>
    <arm_group_label>Placebo for SAD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (Healthy Volunteers):&#xD;
&#xD;
          -  Subject is male or female 18 to 55 yrs old&#xD;
&#xD;
          -  Subject has a BMI 18 to 32 kg/m^2&#xD;
&#xD;
          -  Female and male subjects must use effective method of birth control&#xD;
&#xD;
          -  Female subjects must have negative pregnancy test prior to first dose of study drug&#xD;
&#xD;
          -  Subject must not have any clinically significant eye abnormality&#xD;
&#xD;
          -  Subject must not have any clinically significant history or presence of ECG findings&#xD;
&#xD;
          -  Subject must be in good general health&#xD;
&#xD;
        Inclusion Criteria (PA or MMA Patients):&#xD;
&#xD;
          -  Patient is male or female 18 to 55 yrs old&#xD;
&#xD;
          -  Patient has a BMI 18 to 32 kg/m^2&#xD;
&#xD;
          -  Female and male patients must use effective method of birth control&#xD;
&#xD;
          -  Female patients must have negative pregnancy test prior to first dose of study drug&#xD;
&#xD;
          -  Patient must not have any clinically significant eye abnormality&#xD;
&#xD;
          -  Patient must not have any clinically significant history or presence of ECG findings&#xD;
&#xD;
          -  Patient must have confirmed PA or MMA diagnosis&#xD;
&#xD;
          -  Patient with MMA must have elevated plasma MMA levels&#xD;
&#xD;
          -  Patient is willing to provide access to medical records for the last 6-12 months of&#xD;
             care prior to study initiation&#xD;
&#xD;
          -  Patient is on consistent disease management and treatment regimen is stable for at&#xD;
             least 30 days prior to study initiation.&#xD;
&#xD;
        Exclusion Criteria (Healthy Volunteers):&#xD;
&#xD;
          -  Subject has used prescription drugs within 4 weeks before first dose of study drug or&#xD;
             over-the-counter medication within 7 days of the first dose of study drug&#xD;
&#xD;
          -  Subject who has taken the COVID-19 vaccine, the last vaccine dose must be at least 14&#xD;
             days prior to first dose of study drug.&#xD;
&#xD;
          -  Subject has abnormal laboratory test results&#xD;
&#xD;
          -  Subject has a baseline eGFR &lt;90 mL/minute&#xD;
&#xD;
          -  Subject has positive result for Hepatitis B, Hepatitis C, or HIV&#xD;
&#xD;
          -  Female subject is non-pregnant and non-lactating&#xD;
&#xD;
          -  Subject is a smoker or has used nicotine or nicotine-containing products&#xD;
&#xD;
          -  Subject has a history of alcohol or drug abuse within 12 months prior to first dose of&#xD;
             study drug and/or has a positive result prior to dosing or throughout the study&#xD;
&#xD;
          -  Subject has donated blood or blood products &gt;450mL within 30 days prior to study drug&#xD;
             dosing&#xD;
&#xD;
          -  Subject has a history of relevant drug or food allergies&#xD;
&#xD;
          -  Subject has received study drug in another investigational study within 30 days of&#xD;
             dosing&#xD;
&#xD;
        Exclusion Criteria (PA or MMA Patients):&#xD;
&#xD;
          -  Patient has used prescription drugs within 4 weeks before first dose of study drug or&#xD;
             over-the-counter medication within 7 days of the first dose of study drug that is not&#xD;
             part of their PA or MMA disease management and treatment&#xD;
&#xD;
          -  Patient who has taken the COVID-19 vaccine, the last vaccine dose must be at least 14&#xD;
             days prior to first dose of study drug.&#xD;
&#xD;
          -  Patient has clinically significant abnormal laboratory test results unrelated to PA or&#xD;
             MMA&#xD;
&#xD;
          -  Patient has a baseline eGFR &lt;60 mL/minute&#xD;
&#xD;
          -  Patient has positive result for Hepatitis B, Hepatitis C, or HIV&#xD;
&#xD;
          -  Female patient is non-pregnant and non-lactating&#xD;
&#xD;
          -  Patient is a smoker or has used nicotine or nicotine-containing products&#xD;
&#xD;
          -  Patient has a history of alcohol or drug abuse within 12 months prior to first dose of&#xD;
             study drug and/or has a positive result prior to dosing or throughout the study&#xD;
&#xD;
          -  Patient has donated blood or blood products &gt;450mL within 30 days prior to study drug&#xD;
             dosing&#xD;
&#xD;
          -  Patient has a history of relevant drug or food allergies&#xD;
&#xD;
          -  Patient has received study drug in another investigational study within 30 days of&#xD;
             dosing&#xD;
&#xD;
          -  Patient with PA has undergone prior liver and/or kidney transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Chair</role>
    <affiliation>VP Clinical Development, CoA Therapeutics, Inc., a Bridgebio company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tessa Forbes</last_name>
    <phone>(650) 391-9740</phone>
    <email>tessa.forbes@bridgebio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Community Health Clinic</name>
      <address>
        <city>Topeka</city>
        <state>Indiana</state>
        <zip>46571</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UPMC Children's Hospital of Pittsburg</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>PPD Development, LP</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 29, 2021</study_first_submitted>
  <study_first_submitted_qc>April 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amino Acid Metabolism, Inborn Errors</mesh_term>
    <mesh_term>Propionic Acidemia</mesh_term>
    <mesh_term>Acidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

